Using StrataCTX® to Reduce Steroid Use in CTCL Treatment
Official title: Post-marketing Surveillance of StrataCTX® Flexible Wound Dressing for Use as a Steroid Sparing Agent
Run by Columbia University · NCT04087629 · Data updated 2026-11-12
This study is testing if StrataCTX® can help adults with cutaneous T-cell lymphoma reduce their use of steroids while relieving skin reactions from cancer treatments.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 70 (estimated) |
| Sponsor | Columbia University Academic / other |
| Drugs / interventions | immunotherapy, chemotherapy |
| Locations | 1 site (New York, New York) |
| Status | Recruiting |
| Started | July 7, 2021 |
| Main results expected | August 2027 |
| Study ends | August 2027 |
| Registry record updated | September 11, 2026 |
| Trial ID | NCT04087629 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older with a diagnosis of CTCL who are experiencing skin reactions and are currently reliant on topical steroids.
✕Probably not a fit
Patients currently undergoing radiotherapy or those receiving oral steroids may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to evaluate the effectiveness of StrataCTX® as a steroid-sparing agent for patients with cutaneous T-cell lymphoma (CTCL) experiencing cutaneous reactions due to chemotherapy or immunotherapy. Participants will include adults diagnosed with CTCL who are currently using topical steroids or have developed skin reactions from cancer treatments. The study will assess whether StrataCTX® can provide relief from symptoms while minimizing the reliance on topical steroids, which are associated with various side effects. By comparing the outcomes of StrataCTX® with standard steroid treatments, the study seeks to identify a safer alternative for managing skin-related side effects in these patients.
Why it matters
Potential benefit: If successful, this approach could significantly reduce the need for topical steroids, thereby minimizing their associated side effects for patients with CTCL.
How similar studies have gone: While the use of StrataCTX® is a novel approach, similar studies exploring steroid-sparing strategies have shown promise in managing skin reactions in cancer patients.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Ability to sign informed consent document * Patient with a diagnosis of CTCL who have contact dermatitis to topical mechlorethamine gel * Patients with a diagnosis of CTCL who have intractable pruritis * Patients with a diagnosis of CTCL who rely heavily on topical steroids for symptomatic relief * Patients on chemo/immunotherapy with drug induced rash Exclusion Criteria: * Patients currently undergoing radiotherapy * Patients currently receiving oral steroids * Patients who are unable to apply topical medications
Where it's running
-
Columbia University Irving Medical Center
New York, New York, United States Recruiting
Study contacts
- Principal investigator: Larisa J. Geskin, MD — Columbia University
- Study coordinator: Larisa Geskin, MD
- Email: ljg2145@cumc.columbia.edu
- Phone: 212-305-5293
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Evaluating PTX-100 for patients with relapsed or refractory CTCL
This study is testing a new treatment called PTX-100 to see if it can help people with relapsed or refractory Cutaneous T-Cell Lymphoma feel better.
-
Golidocitinib and chidamide for cutaneous T-cell lymphoma
This study tests whether the combo of golidocitinib and chidamide helps people with CTCL that has already received prior systemic therapy.
-
Evaluating CHT101 for patients with specific blood cancers
This study is testing a new treatment called CHT101 to see if it can help people with certain types of blood cancers that have come back or didn’t respond to other treatments.
-
Golidocitnib treatment for relapsed indolent T/NK-cell lymphomas
This study is testing if a new oral medication called Golidocitnib can help people with relapsed indolent T/NK-cell lymphomas feel better after other treatments haven't worked.
-
Collecting samples to study hairy cell leukemia and develop new cancer treatments
This study is collecting samples from people with hairy cell leukemia and healthy volunteers to see if new treatments can be developed to better fight this type of cancer.
-
CD5 CAR T-cell therapy for relapsed or refractory T-cell lymphoma
This trial tries CD5 CAR T-cell therapy, using either the patient's own cells or donor cells, and may bridge to stem-cell transplant for people 14–70 with relapsed or refractory T-cell lymphoma.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.